Key result
Early atorvastatin prevents LV remodeling in hypertensive rats, reducing LV weight ratio ~15% vs control.
Why the study?
Statins improve left ventricular remodeling in spontaneously hypertensive rats, but the effects of early-stage atorvastatin administration and underlying mechanisms were not fully investigated.
Does atorvastatin prevent left ventricular remodeling in spontaneously hypertensive rats?
Does atorvastatin prevent left ventricular remodeling in spontaneously hypertensive rats?
Early-stage administration of atorvastatin prevents left ventricular remodeling in spontaneously hypertensive rats, potentially by inhibiting myocardial CTGF expression and inducing cardiomyocyte apoptosis.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications in hypertension; leaves open translation of early atorvastatin effects to human LV remodeling.
Statins improve left ventricular (LV) remodeling in spontaneously hypertensive rats (SHRs). This study was designed to investigate the effects of atorvastatin administered in the early stage on LV remodeling in SHRs, and to explore the underlying mechanisms.Sixteen male 8-week-old SHRs were randomized to receive distilled water (SHR-DW) or atorvastatin (SHR-ATV) for 12 weeks. Age-matched male Wistar-Kyoto (WKY) rats gavaged with distilled water served as controls. LV remodeling was evaluated, myocardial CTGF expression levels were detected using Western blotting, and cardiomyocyte apoptosis was detected with the TUNEL method.Compared with WKY and SHR-DW, atorvastatin treatment significantly decreased systolic blood pressure in SHRs; atorvastatin significantly inhibited LV remodeling, as indicated by the reduced LV weight/body weight ratio (SHR-ATV: 4.0 ± 0.4 versus SHR-DW: 4.7 ± 0.4 mg/g, P < 0.05), cardiomyocyte diameter (SHR-ATV: 16.2 ± 2.8 versus SHR-DW: 19.0 ± 1.0 µm, P < 0.05), and interstitial fibrosis (SHR-ATV: 3.3 ± 2.1 versus SHR-DW: 4.5 ± 1.8%, P < 0.05). Compared with WKY, myocardial CTGF expression was significantly increased and cardiomyocyte apoptosis decreased in SHRs. Compared with the SHR-DW group, atorvastatin treatment significantly inhibited myocardial CTGF expression (SHR-ATV: 0.69 ± 0.21 versus SHR-DW: 1.12 ± 0.27, P < 0.05) and induced cardiomyocyte apoptosis in SHRs (SHR-ATV: 5.2 ± 0.6 versus SHR-DW: 1.9 ± 0.3%, P < 0.05).The results indicate that early-stage administration of atorvastatin effectively prevented LV remodeling in SHRs, and that inhibition of myocardial CTGF expression and induction of cardiomyocyte apoptosis may be the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2010) studied Hypertension and Left Ventricular Remodeling (n=24). Atorvastatin vs. Distilled water was evaluated on Left ventricular weight to body weight ratio (mg/g) (p=<0.05). Early-stage administration of atorvastatin prevented left ventricular remodeling in spontaneously hypertensive rats, reducing the LV weight to body weight ratio compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: